Trial
NCT03630640
Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Bristol-Myers Squibb
Condition
Hepatocellular Carcinoma
Intervention
Nivolumab Injection [Opdivo]
Why stopped
Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding partner halted enrollment at that time to meet contractual obligations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24